Q2 2025 Vicarious Surgical Inc Earnings Call Transcript
Key Points
- Vicarious Surgical Inc (RBOT) has appointed a new CEO, Stephen From, who brings a strong track record in healthcare and medtech industries.
- The company reported a 24% decrease in total operating expenses for Q2 2025 compared to the same period in 2024.
- Research and development expenses decreased from $10.9 million in Q2 2024 to $9.1 million in Q2 2025.
- General and administrative expenses were reduced from $5.6 million in Q2 2024 to $4.1 million in Q2 2025.
- The company ended Q2 2025 with approximately $24 million in cash, cash equivalents, and short-term investments, indicating a strong cash position.
- The company has decided to delay its first clinical use (FCU) trial to focus on completing a production-equivalent system, impacting near-term clinical milestones.
- Vicarious Surgical Inc (RBOT) reported a GAAP net loss of $13.2 million for Q2 2025, although this is an improvement from the previous year.
- The cash burn rate for Q2 2025 was approximately $13.4 million, with expectations of a full-year cash burn of around $50 million.
- The timeline for future clinical trials and FDA submissions remains uncertain, pending a comprehensive assessment of the system's readiness.
- The company faces challenges in the competitive robotic surgery market, which is dominated by a major player, and must ensure its technology is sufficiently differentiated.
Good afternoon. Thank you for attending the Vicarious Surgical's 2025 second-quarter earnings call. My name is Cameron, and I'll be your moderator for today. (Operator Instructions)
And I would now like to pass the conference over to your host, Marissa Bych from the Gilmartin Group. You may proceed.
Good afternoon. Today, after market close, Vicarious Surgical released financial results for the three months ended June 30, 2025. A copy of the press release is available on the company website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Hbarbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
